Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15569388 | 0.84 | MAPT (0.62) | LMNAMAPTSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL31452925 | 0.82 | MEN1 (0.66) | LMNAMAPTSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL4172495 | 0.81 | MAPT (0.58) | LMNAMAPTSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL15956633 | 0.80 | MAPT (0.57) | LMNAMAPTSMN1; SMN2KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL5071255 | 0.80 | MAPT (0.57) | LMNAMAPTSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL1440000 | 0.78 | MAPT (0.55) | LMNAMAPTSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL30924929 | 0.78 | MAPT (0.55) | LMNAMAPTSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL853489 | 0.78 | MAPT (0.55) | LMNAMAPTSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL30414662 | 0.78 | MAPT (0.55) | LMNAMAPTSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL6950591 | 0.78 | MAPT (0.55) | LMNAMAPTSMN1; SMN2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190153157-A1 | THERMOGELLING SUPRAMOLECULAR SPONGE AS SELF-HEALING AND BIOCOMPATIBLE HYDROGEL | JULIUS-MAXIMILIANS-UNIVERSITAET WUERZBURG (DE) | 2019-05-23 | — | — | US | disclosed |
| US-7795267-B2 | Bicyclic piperazine compound having TGR23 antagonistic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-14 | — | — | US | disclosed |
| US-7795267-B2 | Bicyclic piperazine compound having TGR23 antagonistic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-14 | — | — | US | disclosed |
| US-20070072865-A1 | Bicyclic piperazine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-29 | — | — | US | disclosed |
| US-20070072865-A1 | Bicyclic piperazine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072865-A1 | Bicyclic piperazine compound and use thereof | GPR3, FFAR3, LPAR3 | LMNA 4583/4885MAPT 4830/4885SMN1; SMN2 4533/4885 |
| US-20190153157-A1 | THERMOGELLING SUPRAMOLECULAR SPONGE AS SELF-HEALING AND BIOCOMPATIBLE HYDROGEL | BOLA2; BOLA2B, HSPA1B, HSPB1 | LMNA 989/4885MAPT 4763/4885SMN1; SMN2 1430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.